Historical Valuation
CLOVER BIO-B (02197) is now in the Overvalued zone, suggesting that its current forward PS ratio of 3.90 is considered Overvalued compared with the five-year average of 9.66. The fair price of CLOVER BIO-B (02197) is between 0.05 to 1.93 according to relative valuation methord. Compared to the current price of 2.80 USD , CLOVER BIO-B is Overvalued By 45.33%.
Relative Value
Fair Zone
0.05-1.93
Current Price：2.80
45.33%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
CLOVER BIO-B (02197) has a current Price-to-Book (P/B) ratio of -1.71. Compared to its 3-year average P/B ratio of 7.83 , the current P/B ratio is approximately -121.80% higher. Relative to its 5-year average P/B ratio of 8.26, the current P/B ratio is about -120.66% higher. CLOVER BIO-B (02197) has a Forward Free Cash Flow (FCF) yield of approximately -8.93%. Compared to its 3-year average FCF yield of -99.94%, the current FCF yield is approximately -91.07% lower. Relative to its 5-year average FCF yield of -78.98% , the current FCF yield is about -88.69% lower.
P/B
Median3y
7.83
Median5y
8.26
FCF Yield
Median3y
-99.94
Median5y
-78.98
Performance Decomposition
AI Analysis for 02197
1Y
3Y
5Y
Market capitalization of 02197 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 02197 in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is 02197 currently overvalued or undervalued?
CLOVER BIO-B (02197) is now in the Overvalued zone, suggesting that its current forward PS ratio of 3.90 is considered Overvalued compared with the five-year average of 9.66. The fair price of CLOVER BIO-B (02197) is between 0.05 to 1.93 according to relative valuation methord. Compared to the current price of 2.80 USD , CLOVER BIO-B is Overvalued By 45.33% .
What is CLOVER BIO-B (02197) fair value?
02197's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of CLOVER BIO-B (02197) is between 0.05 to 1.93 according to relative valuation methord.
How does 02197's valuation metrics compare to the industry average?
The average P/S ratio for 02197's competitors is , providing a benchmark for relative valuation. CLOVER BIO-B Corp (02197) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for CLOVER BIO-B (02197) as of Jan 12 2026?
As of Jan 12 2026, CLOVER BIO-B (02197) has a P/B ratio of -1.71. This indicates that the market values 02197 at -1.71 times its book value.
What is the current FCF Yield for CLOVER BIO-B (02197) as of Jan 12 2026?
As of Jan 12 2026, CLOVER BIO-B (02197) has a FCF Yield of -8.93%. This means that for every dollar of CLOVER BIO-B’s market capitalization, the company generates -8.93 cents in free cash flow.
What is the current Forward P/E ratio for CLOVER BIO-B (02197) as of Jan 12 2026?
As of Jan 12 2026, CLOVER BIO-B (02197) has a Forward P/E ratio of 56.10. This means the market is willing to pay $56.10 for every dollar of CLOVER BIO-B’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for CLOVER BIO-B (02197) as of Jan 12 2026?
As of Jan 12 2026, CLOVER BIO-B (02197) has a Forward P/S ratio of 3.90. This means the market is valuing 02197 at $3.90 for every dollar of expected revenue over the next 12 months.